Ovarian cancer patients treated with AstraZeneca’s Lynparza medication may see their life expectancy dramatically increase, according to results of a Phase III clinical trial.
Patients given two 300 mg Lynparza pills lived four to six times longer without relapse than patients on placebo, according to an AstraZeneca press release. The results were recently announced at the annual Society of Gynecological Oncology meeting on Women’s Cancer held in National Harbor.
Eric Pujade-Lauraine, Head of the Women Cancers and Clinical Research Department at Hopitaux Universitaires Paris Center, said in the release that the results as “very encouraging."
“Most importantly, patients were able to maintain quality of life while experiencing an impressive delay in disease progression, demonstrating the benefits of Lynparza tablets for these women whose cancer is often difficult to treat,” he said.
Sean Bohen, AstraZeneca’s executive vice president of global medicines development and chief medical officer, said now that Phase III of the trial is over, the company aims to quickly bring Lynparza to market.
“The tablet formulation may offer patients a reduced pill burden for Lynparza and a safety profile that is generally consistent with previous trials,” Bohen said in the release.
